Respiratory Syncytial Virus Infections
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infections.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: mResvia (Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation) — Moderna Biotech Spain, S.L.
mResvia, an mRNA vaccine encoding RSV F protein in prefusion conformation, has been authorised in the EU for respiratory syncytial virus inf…
-
EMA approval · 2026-08-06EMA Authorised: Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)) — Pfizer Europe MA EEIG
EMA has authorised Abrysvo, a bivalent recombinant RSV vaccine, for respiratory syncytial virus infections with accelerated assessment.
-
EMA approval · 2026-03-23EMA Authorised: Arexvy — GlaxoSmithKline Biologicals S.A.
The EMA has authorised Arexvy by GlaxoSmithKline Biologicals S.A. for respiratory syncytial virus infections. Decision date: 19 February 202…
-
EMA approval · 2025-11-26EMA Authorised: mResvia (Respiratory syncytial virus mRNA vaccine (nucleoside modified)) — Moderna Biotech Spain, S.L.
The EMA has authorised mResvia, a nucleoside-modified RSV mRNA vaccine by Moderna Biotech Spain, S.L., for prevention of respiratory syncyti…